mgmt methylation testing Search Results


mgmt promoter methylation testing  (MDxHealth)
90
MDxHealth mgmt promoter methylation testing
Mgmt Promoter Methylation Testing, supplied by MDxHealth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mgmt promoter methylation testing/product/MDxHealth
Average 90 stars, based on 1 article reviews
mgmt promoter methylation testing - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
mgmt methylation testing  (LabCorp)
90
LabCorp mgmt methylation testing
Mutations and copy number variants (CNVs) from WES are shown for core glioma genetic drivers. When available (n=55), patient germline variants were subtracted. Molecular gene expression subtype was determined from RNAseq (14). DNA <t>methylation</t> group was determined from genome wide methylation profiling according to TCGA pan-glioma classification (15). <t>MGMT</t> promoter methylation was assessed by quantitative methylation-specific PCR performed at Mayo Clinic. TERT promoter mutations (C228T and C250T) were detected by Sanger sequencing.
Mgmt Methylation Testing, supplied by LabCorp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mgmt methylation testing/product/LabCorp
Average 90 stars, based on 1 article reviews
mgmt methylation testing - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Mutations and copy number variants (CNVs) from WES are shown for core glioma genetic drivers. When available (n=55), patient germline variants were subtracted. Molecular gene expression subtype was determined from RNAseq (14). DNA methylation group was determined from genome wide methylation profiling according to TCGA pan-glioma classification (15). MGMT promoter methylation was assessed by quantitative methylation-specific PCR performed at Mayo Clinic. TERT promoter mutations (C228T and C250T) were detected by Sanger sequencing.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Genomic and phenotypic characterization of a broad panel of patient derived xenografts reflects the diversity of glioblastoma

doi: 10.1158/1078-0432.CCR-19-0909

Figure Lengend Snippet: Mutations and copy number variants (CNVs) from WES are shown for core glioma genetic drivers. When available (n=55), patient germline variants were subtracted. Molecular gene expression subtype was determined from RNAseq (14). DNA methylation group was determined from genome wide methylation profiling according to TCGA pan-glioma classification (15). MGMT promoter methylation was assessed by quantitative methylation-specific PCR performed at Mayo Clinic. TERT promoter mutations (C228T and C250T) were detected by Sanger sequencing.

Article Snippet: For 22 patients, MGMT methylation was assessed during clinical care; the majority of testing was performed at LabCorp (Burlington, NC).

Techniques: Gene Expression, DNA Methylation Assay, Genome Wide, Methylation, Sequencing

(A) Survival benefit across PDX models treated with RT, TMZ and RT/TMZ. Mice with established orthotopic tumors from 37 PDX lines were randomized to treatment with RT, TMZ, or RT/TMZ. Survival benefit was calculated as a ratio of survival of the treated mice to placebo treated mice. PDXs are grouped by MGMT status: M=MGMT methylated (N=14), U=MGMT unmethylated (N=14) and R=recurrent (N=9). (B) Comparison of patient and PDX survival following standard therapies for 20 matched pairs with xenografts established at initial diagnosis. Patient survival is shown in months and PDX survival in days.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Genomic and phenotypic characterization of a broad panel of patient derived xenografts reflects the diversity of glioblastoma

doi: 10.1158/1078-0432.CCR-19-0909

Figure Lengend Snippet: (A) Survival benefit across PDX models treated with RT, TMZ and RT/TMZ. Mice with established orthotopic tumors from 37 PDX lines were randomized to treatment with RT, TMZ, or RT/TMZ. Survival benefit was calculated as a ratio of survival of the treated mice to placebo treated mice. PDXs are grouped by MGMT status: M=MGMT methylated (N=14), U=MGMT unmethylated (N=14) and R=recurrent (N=9). (B) Comparison of patient and PDX survival following standard therapies for 20 matched pairs with xenografts established at initial diagnosis. Patient survival is shown in months and PDX survival in days.

Article Snippet: For 22 patients, MGMT methylation was assessed during clinical care; the majority of testing was performed at LabCorp (Burlington, NC).

Techniques: Methylation, Comparison, Biomarker Discovery